BACKGROUND: The formation of biofilms is crucial in the pathogenesis of many acute and subacute microbial infections, including chronic wounds and foreign-body-related infections. Topical antimicrobial therapy with chemical antiseptics or physical treatment with tissue-tolerable plasma (TTP) may be promising to control bacterial infection. METHODS: We assessed the efficacy of 0.1% chlorhexidine digluconate (CHX), 0.02 and 0.04% polihexanide (polyhexamethylene biguanide, PHMB) and of TTP against Pseudomonas aeruginosa SG81 biofilm grown in microtitre plates (polystyrene) and on silicone materials in an artificial wound fluid. RESULTS: Overall, PHMB was as effective as CHX in reducing the total amount of biofilm (gentian violet assay) and in reducing the bacterial metabolism in biofilms (XTT assay). TTP also led to a significant reduction in colony-forming units. CONCLUSION: The antimicrobial activity of PHMB in biofilms is comparable to that of CHX. TTP could become an interesting physical alternative to chemical antisepsis in the future.
BACKGROUND: The formation of biofilms is crucial in the pathogenesis of many acute and subacute microbial infections, including chronic wounds and foreign-body-related infections. Topical antimicrobial therapy with chemical antiseptics or physical treatment with tissue-tolerable plasma (TTP) may be promising to control bacterial infection. METHODS: We assessed the efficacy of 0.1% chlorhexidine digluconate (CHX), 0.02 and 0.04% polihexanide (polyhexamethylene biguanide, PHMB) and of TTP against Pseudomonas aeruginosa SG81 biofilm grown in microtitre plates (polystyrene) and on silicone materials in an artificial wound fluid. RESULTS: Overall, PHMB was as effective as CHX in reducing the total amount of biofilm (gentian violet assay) and in reducing the bacterial metabolism in biofilms (XTT assay). TTP also led to a significant reduction in colony-forming units. CONCLUSION: The antimicrobial activity of PHMB in biofilms is comparable to that of CHX. TTP could become an interesting physical alternative to chemical antisepsis in the future.
Authors: Stephen C Davis; Andrew Harding; Joel Gil; Fernando Parajon; Jose Valdes; Michael Solis; Alex Higa Journal: Int Wound J Date: 2017-03-07 Impact factor: 3.315
Authors: Philipp Pierdzioch; Stefan Hartwig; Sascha R Herbst; Jan Dirk Raguse; Henrik Dommisch; Shady Abu-Sirhan; Henrik C Wirtz; Moritz Hertel; Sebastian Paris; Saskia Preissner Journal: Clin Oral Investig Date: 2016-01-19 Impact factor: 3.573
Authors: Richard Birk; C Aderhold; J Stern-Sträter; K Hörmann; B A Stuck; J U Sommer Journal: Eur Arch Otorhinolaryngol Date: 2014-06-06 Impact factor: 2.503
Authors: Stefan Rupf; Ahmad Nour Idlibi; Fuad Al Marrawi; Matthias Hannig; Andreas Schubert; Lutz von Mueller; Wolfgang Spitzer; Henrik Holtmann; Antje Lehmann; Andre Rueppell; Axel Schindler Journal: PLoS One Date: 2011-10-10 Impact factor: 3.240
Authors: Ina Koban; Rutger Matthes; Nils-Olaf Hübner; Alexander Welk; Rabea Sietmann; Jürgen Lademann; Axel Kramer; Thomas Kocher Journal: GMS Krankenhhyg Interdiszip Date: 2012-04-04
Authors: Susanne Gorynia; Ina Koban; Rutger Matthes; Alexander Welk; Sabine Gorynia; Nils-Olaf Hübner; Thomas Kocher; Axel Kramer Journal: GMS Hyg Infect Control Date: 2013-04-29
Authors: Rutger Matthes; Claudia Bender; Rabea Schlüter; Ina Koban; René Bussiahn; Stephan Reuter; Jürgen Lademann; Klaus-Dieter Weltmann; Axel Kramer Journal: PLoS One Date: 2013-07-24 Impact factor: 3.240